- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06204549
Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk (COMMEDCARDIO)
Impact du Bilan et de la Prise en Charge Des comorbidités en médecine Interne Sur le Risque Cardiovasculaire
The aim of assessing and managing cardiovascular risk is to avoid, limit or delay cardiovascular morbidity and mortality. Planned internal medicine hospitalization is developed around the management of cardiovascular risk in patients at high cardiovascular risk, whether in primary prevention or secondary prevention.
During planned hospitalization, patients benefit from comprehensive, personalized and adapted care for their comorbidities and their CVRF (cardiovascular risk factors).
This study will make it possible to evaluate this overall course of multidisciplinary management of comorbidities of patients at high cardiovascular risk.
Study Overview
Status
Intervention / Treatment
Detailed Description
The aim of assessing and managing cardiovascular risk is to avoid, limit or delay cardiovascular morbidity and mortality. Planned internal medicine is developed around the management of cardiovascular risk in patients at high cardiovascular risk, whether in primary prevention patients, combining several cardiovascular risk factors CVRF (arterial hypertension, metabolic syndrome, diabetes, dyslipidemia, etc.), or patients in secondary prevention who have several CVRFs and have already had a major cardiovascular event such as ischemic heart disease, heart failure.
During scheduled hospitalization, patients benefit from comprehensive care. Additional examinations include measurement of blood pressure, cardiac ultrasound, vascular Dopplers, usual biological assessment (lipid, glycemic, renal, iron assessment, CRP), and on a case-by-case basis, ventilatory polygraphy to screen for obstructive sleep apnea hypopnea syndrome, pulmonary function tests if the patient is a smoker to screen for chronic obstructive pulmonary disease, coronary function test to screen for ischemic heart disease if indicated. Comorbidities are thus identified and summarized, and patients benefit from personalized and adapted care for their comorbidities and CVRFs.
Cardiovascular risk reduction strategy programs targeting high-risk patients are essential and their evaluation is necessary.This study will make it possible to evaluate this overall course of multidisciplinary management of comorbidities in patients at high cardiovascular risk in internal medicine.
The innovative nature of the project is the possibility to cross-reference the comorbidities and the cardiovascular and metabolic data of these patients at high cardiovascular risk with their evolving risk level over time. This will also make it possible to highlight which markers are the most effective to better stratify cardiovascular risk, or even consider personalized phenotyping. The coexistence of all these parameters within the same database represents a unique opportunity to study their respective influences in a population of patients at high cardiovascular risk.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Fanny CARDON
- Phone Number: 0033 4 67 33 08 24
- Email: fanny-cardon@chu-montpellier.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
High-Risk Cardiovascular patients either receiving:
- Primary prevention because they have never had a cardiovascular event but have several cardiovascular risk factors such as high blood pressure particularly resistant, metabolic syndrome, diabetes , dyslipidemia, metabolic steatosis
- Or secondary prevention because they have already had a major cardiovascular event such as ischemic heart disease, heart failure
- Aged 18 and over
- Patient benefiting from comorbidities assessment during their planned hospitalization in the internal medicine department.
Exclusion Criteria:
- Patient refusal
- Subject not registered in social security system
- Pregnant or breastfeeding woman
- Patient unable to give their informed consent, protected adult, vulnerable people
- Subject deprived of liberty by judicial or administrative decision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Comorbidities screening and management
|
During the routine care assessment and as part of the research, patients will :
After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Screening and management of comorbidities effect on cardiovascular risk factors
Time Frame: 3 months after enrollment
|
Effect of comorbidities screening and management on cardiovascular risk factors in patients at high-risk of a cardiovascular event. The life's simple 7 score will be used at enrollment and 3 months afterward. The score includes four modifiable behaviors (smoking, weight, healthy/unhealthy eating diet and physical activity) and three biometric measures (blood pressure, cholesterol and blood sugar level). These seven factors are classified into three categories: ideal, intermediate and poor. Life's Simple 7 summary score ranges from 0 to a maximum of 14 points, with a higher score indicating healthier status. |
3 months after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Screening and management of comorbidities effect on cardiovascular risk factors
Time Frame: 12 months after enrollment
|
Effect of comorbidities screening and management on cardiovascular risk factors in patients at high-risk of a cardiovascular event. The life's simple 7 score will be used at 12 months after enrollment. The score includes four modifiable behaviors (smoking, weight, healthy/unhealthy eating diet and physical activity) and three biometric measures (blood pressure, cholesterol and blood sugar level). These seven factors are classified into three categories: ideal, intermediate and poor. Life's Simple 7 summary score ranges from 0 to a maximum of 14 points, with a higher score indicating healthier status. |
12 months after enrollment
|
Screening and management of comorbidities effect on blood pressure
Time Frame: 3 and 12 months after enrollment
|
Effect of comorbidities screening and management on the evolution of cardiovascular risk factor "blood pressure" 3 and 12 months after hospital discharge compared to hospitalization. Measurement method: Holter blood pressure measurement during hospitalization, and self-measured blood pressure average over 3 days at 3 and 12 months after hospitalization using cuff device for self-measurement. |
3 and 12 months after enrollment
|
Screening and management of comorbidities effect on patient's weight
Time Frame: 3 and 12 months after enrollment
|
Effect of comorbidities screening and management on the evolution of cardiovascular risk factor "weight" at 3 and 12 months after hospital discharge compared to hospitalization. The patient's weight will be measured using a weighing scale. |
3 and 12 months after enrollment
|
Screening and management of comorbidities effect on the balance of cholesterol
Time Frame: 3 and 12 months after enrollment
|
Effect of comorbidities screening and management on cardiovascular risk factor "cholesterol" by evaluating the evolution at 3 and 12 months after hospital discharge compared to hospitalization of biological tests: HDL (high-density lipoprotein), LDL(low-density lipoprotein) and triglycerides.
|
3 and 12 months after enrollment
|
Screening and management of comorbidities effect on tobacco consumption
Time Frame: 3 and 12 months after enrollment
|
Effect of comorbidities screening and management on the evolution of cardiovascular risk factor "tobacco consumption" (weaned or still acive,level of consumption) at 3 and 12 months after hospital discharge compared to hospitalization.
|
3 and 12 months after enrollment
|
Screening and management of comorbidities effect on the balance of blood sugar level
Time Frame: 3 and 12 months after enrollment
|
Effect of comorbidities screening and management on cardiovascular risk factor "blood sugar" by evaluating the evolution of fasting blood sugar test results at 3 and 12 months after hospital discharge compared to hospitalization.
|
3 and 12 months after enrollment
|
Screening and management of comorbidities effect on A1C level
Time Frame: 3 and 12 months after enrollment
|
Effect of comorbidities screening and management on the evolution of A1C test results at 3 and 12 months after hospital discharge compared to hospitalization in diabetic patients.
|
3 and 12 months after enrollment
|
Cardivascular events incidence
Time Frame: 12 months after enrollment
|
Description of the incidence of cardiovascular events including cardiovascular mortality.
|
12 months after enrollment
|
Initial participant's comorbidities
Time Frame: At enrollment
|
Exploration of demographic characteristics and initial comorbidities as factors associated with the evolution of cardiovascular risk factors and markers, for cardiovascular risk stratification purpose. Charlson Comorbidity Index (CCI) will be used at enrollment.The Index assesses comorbidity level by taking into account both the number and severity of 19 pre-defined comorbid conditions. It provides a weighted score of a patient's comorbidities which can be used to predict short term and long-term outcomes such as function, hospital length of stay and mortality rates.The total score in the CCI is derived by summing the assigned weights of all comorbid conditions presented by the patient. Higher scores indicate a more severe condition and consequently, a worse prognosis. |
At enrollment
|
C-reactive protein levels
Time Frame: At enrollment
|
Exploration of C-reactive protein (CRP) levels as an associated factor with the evolution of cardiovascular risk markers for cardiovascular risk stratification purpose
|
At enrollment
|
Lipoprotein a levels
Time Frame: At enrollment
|
Exploration of Lipoprotein a levels as an associated factor with the evolution of cardiovascular risk factors and markers for cardiovascular risk stratification purpose.
|
At enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Camille ROUBILLE, MD, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RECHMPL22_0390 UF 8366
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients at High-Risk of a Cardiovascular Event
-
Nova Scotia Health AuthorityPfizer; Cape Breton District Health AuthorityCompletedCardiovascular Risk Reduction of Having a Coronary EventCanada
-
Queen's University, BelfastCompletedPatients at High Risk of Medicine-related ProblemsUnited Kingdom
-
Wake Forest University Health SciencesCompletedUnplanned Hospital Readmissions | Patients at High Risk of Unplanned ReadmissionUnited States
-
Centre Hospitalier Universitaire DijonTerminatedHigh Cardiovascular Risk Patients | Low Cardiovascular Risk PatientsFrance
-
University of ChicagoNorthwestern University; University of Illinois at Chicago; Rush University Medical... and other collaboratorsActive, not recruitingMedicare Patients | High Risk of HospitalizationsUnited States
-
University Hospital of CologneKarolinska Institutet; University Hospital of North Norway; Goethe University; McGill... and other collaboratorsUnknownPatients at High Risk of Antibacterial Treatment Upon AdmissionGermany
-
Frederiksberg University HospitalCompleted
-
Mental Health Services in the Capital Region, DenmarkCopenhagen Trial Unit, Center for Clinical Intervention Research; Center for...CompletedPatients at Ultra-high Risk of PsychosisDenmark
-
Yonsei UniversityRecruitingHigh Risk Cardiovascular Disease PatientsKorea, Republic of
-
Portsmouth Hospitals NHS TrustRecruitingAdult Hospital Patients at Risk of Adverse OutcomesUnited Kingdom
Clinical Trials on Screening and management of cormobidities
-
Lawson Health Research InstituteOntario Ministry of Health and Long Term Care; Canadian Mental Health Association and other collaboratorsCompletedPsychotic Disorders | Diabetes Mellitus | SchizophreniaCanada
-
Lawson Health Research InstituteEli Lilly and Company; St. Joseph's Health Care LondonCompletedPsychotic Disorders | Diabetes Mellitus | SchizophreniaCanada
-
VA Office of Research and DevelopmentMalcom Randall VA Medical Center; Richard L. Roudebush VA Medical CenterCompletedMental Health | Health Services | NeurologyUnited States
-
Institute of Tropical Medicine, BelgiumEcole Nationale de Santé Publique, Rabat, MoroccoCompletedGestational Diabetes Mellitus in PregnancyMorocco
-
Shanghai Eye Disease Prevention and Treatment CenterUnknown
-
Clinical Directors NetworkCompletedDepression | Cervical Cancer Screening | Breast Cancer Screening | Colorectal Cancer ScreeningUnited States
-
Shanghai Changzheng HospitalUnknownCardiovascular Disease | Lung Neoplasms | Chronic Obstructive Pulmonary Disease | Mass ScreeningChina
-
Dana-Farber Cancer InstituteCompletedHematologic MalignancyUnited States
-
Case Comprehensive Cancer CenterTerminatedAdolescent and Young Adult CancerUnited States
-
ASP 7 RagusaNot yet recruitingMultiple Sclerosis | Urinary Bladder, NeurogenicItaly